Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials

INTRODUCTION: Interleukin-17 inhibitors are the newest class of monoclonal antibodies approved by the US Food and Drug Administration for the treatment of psoriasis. Preclinical and Phase II studies of ixekizumab, a high-affinity anti-IL-17A monoclonal antibody, have proved promising. METHODS: We co...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Dermatol Ther (Heidelb)
Egile Nagusiak: Farahnik, Benjamin, Beroukhim, Kourosh, Zhu, Tian Hao, Abrouk, Michael, Nakamura, Mio, Singh, Rasnik, Lee, Kristina, Bhutani, Tina, Koo, John
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer Healthcare 2016
Gaiak:
Review
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4799032/
https://ncbi.nlm.nih.gov/pubmed/26910853
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13555-016-0102-0
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak